ClinicalTrials.gg
Enrolling by invitationNCT07372651OPT-AIUpdated Jan 28, 2026

OPTimising a Screening Program to Detect Pacemaker-associated Heart Failure Using Artificial Intelligence

An observational study in Heart Failure and Pacemaker, sponsored by University of Leeds. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by University of Leeds · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Heart Failure by University of Leeds — 4 open to participants now, 5 under way, none of them phase 3. Heart Failure · University of Leeds.

Started
2025
with 1 other
Observational
5 of 15
4 open now
Registered
13th of 15
by date

Among the 15 studies in Heart Failure by University of Leeds, this one is one of 2 that started in 2025, is one of 5 observational ones, and was the 13th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

4 of the 15 studies in Heart Failure by University of Leeds are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Heart Failure by University of Leeds, or all of them as a file.
02

Study summary

Pacemakers are an effective treatment for slow heart rates which improve symptoms and save lives. However, for some people pacemakers can cause heart failure (HF) because of the unnatural way in which they stimulate heart beats. In several studies conducted in West Yorkshire we showed that \~1/3 of patients with pacemakers have undiagnosed HF. We also showed that where HF is discovered, treating it with safe and inexpensive medications reduces the chances of being admitted to hospital or dying. However, detecting HF requires an echocardiogram (a heart ultrasound scan) which takes \~45 minutes, requires a skilled technician, and costs £120; or, to put it another way \~£540,000 to assess the \~4,500 patients cared for at our hospital. A new approach is needed. We think that using new technologies can improve our ability to screen for HF in people with pacemakers. We will test two approaches. First, we will assess whether a hand-held echocardiogram can measure heart function using artificial intelligence (AI) as accurately as a standard echocardiogram done by a skilled technician. Second, we will assess whether a finger-prick blood test can detect the presence of abnormal function as accurately as a standard echocardiogram.

Read the detailed description

Pacemakers are an effective treatment for slow heart rates which improve symptoms and save lives. However, for some people pacemakers can cause heart failure (HF) because of the unnatural way in which they stimulate heart beats. In several studies conducted in West Yorkshire we showed that \~1/3 of patients with pacemakers have undiagnosed HF. We also showed that where HF is discovered, treating it with safe and inexpensive medications reduces the chances of being admitted to hospital or dying. However, detecting HF requires an echocardiogram (a heart ultrasound scan) which takes \~45 minutes, requires a skilled technician, and costs £120; or, to put it another way \~£540,000 to assess the \~4,500 patients in Leeds. A new approach is needed. We think that using new technologies might improve our ability to screen for HF in people with pacemakers. Hand-held devices which are capable of cardiac imaging, and measurement of heart failure using Artificial Intelligence (AI) are now commercially available. However, these devices have not been specifically developed to detect heart dysfunction in people with pacemakers. Pacemakers result in a specific form of heart muscle weakness which is different to that caused by other conditions which result in HF, therefore it is essential to prove its accuracy before use in routine clinical practice. Another possible way to detect heart muscle weakness is by first screening patients with a blood test. N-terminal B- type natriuretic peptide (NT-proBNP) is a peptide released by the heart in response to strain or stress, and usually elevated in people with heart failure. Devices are now commercially available which can provide a measurement of NT-proBNP from a finger prick blood test, and crucially within a few minutes so that the result might be known during a patients routine appointment. Whilst this blood test cannot provide a diagnosis, it might help identify individuals who are at higher risk and should go on to have a standard echocardiogram.

To make participation as simple as possible, and to avoid unnecessary visits to the hospital, patients will be approached prior to their routine pacemaker clinic appointment. Patients who have pacemakers attend the hospital every 6-12 months in person to undergo a check of their pacemaker's battery life and function. All potential participants will be identified by a member the patient's direct care team according to the study inclusion criteria. We will recruit patients with pacemakers and right ventricular pacing burden (the percentage of heat beats which are due to the pacemaker) ≥20% - this is important as we know that the risk of heart muscle weakness is correlated with the percentage of paced beats, with ≥20% being an accepted cut-off supported by our own data. We will exclude patients unable or unwilling to participate. We will also exclude patients with cardiac devices which mitigate against the risk of heart muscle weakness, or those likely to have been implanted for the management of known heart failure (conduction system pacemakers, cardiac resynchronisation therapy pacemakers/defibrillators, implantable cardioverter defibrillators, leadless pacemakers, single chamber atrial pacemakers).

Potential participants will be sent an Invitation Letter and the Patient Information Sheet, offering them the opportunity to attend an appointment in the Leeds Cardiovascular Clinical Research Facility instead of their usual pacemaker clinic appointment. This will then be followed up by a telephone call from the direct care team, and only those who are potentially interested and confirm their agreement to have their information passed to the research team will be approached to arrange an appointment. On the day of the appointment, a member of the research team will approach the patient, explain the study and offer the opportunity to ask questions. Participants will have already had at least one week to read the Participants Information Sheet and consider whether they wish to take part. If willing to participate, they will then provide written consent to undertake the study procedures. All patients, regardless of whether they consent to participate, or not, will have a pacemaker safety check by an accredited cardiac physiologist. If patients agree to participate their appointment would last around one hour, for comparison a routine pacemaker appointment lasts around 20 minutes. Following the appointment their next appointment with their usual care team will be scheduled.

Generic study procedures: Participants will undergo a routine device interrogation by an accredited cardiac physiologist as per usual clinical care to confirm device functionality and right ventricular pacing burden ≥20%. For participants who consent to participate the research team will collect demographic and clinical information from their electronic healthcare record. Participants will then undergo point-of-care blood testing for NTpro-BNP, a hand-held echocardiogram and a standard cart-based echocardiogram. Point-of-care NTpro-BNP blood testing: LumiraDx (LumiraDx Ltd, Cayman Islands) is a quantitative point-of-care, fingerpick blood test capable of measuring various biomarkers using a micro-sample of blood obtained from a finger prick. NT-proBNP is a routine blood test used to diagnose and monitor heart failure. The LumiraDx can measure NTpro-BNP with only 20uL of blood, is highly portable, with a turn-around time of only 12 minutes - feasible within the time constraints of a standard pacemaker follow-up appointment. For the patient, this entails having a small quantify of blood taken from a finger prick. The process results in very minimal discomfort and is almost identical to blood sugar testing patients with diabetes are requiring to do several times per day. Afterwards a small amount of cotton wool is placed on the finger tip and pressure applied. Their technology has been validated in a study of 659 samples compared to gold-standard commercially available laboratory equipment (Roche Cobas Elecsys proBNP II assay) and found to have comparable accuracy (slope 0.86, intercept -4.12, r 0.97).

Hand-held cardiac ultrasound: participants will undergo a focussed hand-held echocardiogram with AI derived LVEF using the Kosmos platform (EchoNous Inc., Redmond, USA) a point-of-care, hand-held ultrasound device capable of cardiac imaging, which uses US2.AI (Ultrasound Anyone Anywhere, Singapore) integrated AI driven software capable of automated measurement of LVEF. The Kosmos platform assists the operator to obtain optimal images, prompts the image to be acquired when the image has been optimised, and provides an immediate measurement of LVEF. Existing data suggest the Kosmos platform is able to reliably detect abnormal LVEF in patients referred with suspected HF, however there are no data describing its use in a population with pacing-induced left ventricular dysfunction. Hand-held echocardiography will be done by a specialist nurse or cardiac physiologist who does not hold accreditation in echocardiography. They will have previously received focussed training in obtaining the images required, which will be deliberately limited (≤1 day) so as to ensure our findings are generalisable to teams without experience of echocardiography.

Standard cart-based cardiac ultrasound: participants will undergo a transthoracic echocardiogram by a senior cardiac physiologist accredited by the British Society of Echocardiography (or equivalent international body) using a GE Healthcare Vivid E95 Ultra Edition Cardiac Ultrasound. For the participant this involves lying semi-reclined on a couch, with ultrasound images obtained from four locations on the chest wall. The scan takes around 25 minutes to obtain the images (with an additional 20 minutes to take measurements and prepare the report) and poses no risk to the patient. A minimum dataset will be obtained with LVEF measured by the biplane method where possible, as well as assess for any (at least) moderate valvular disease or other finding which could result in a change to patient management.

This is a cross-sectional study, participants will be assessed at a single point in time. Provided there are no abnormal findings, participants will then be booked to attend their next scheduled pacemaker follow-up appointment as planned.

Any serious adverse event (SAE) occurring in a research participant, where, in the opinion of the Chief Investigator the event was related to the administration of any of the research procedures will be reported to the Sponsor (governance- ethics@leeds.ac.uk) within one working day of the research team's awareness. SAE will be recorded during the participant's visit, and documented in the electronic healthcare record. Untoward events which occur after the study visit has been completed or are not directly related to the study visit will not be reported. It is anticipated that during this study we will identify important heart muscle weakness, or other abnormal findings on cardiac ultrasound. These findings, and any untoward event which occur as a consequence of new diagnoses/findings (such as hospitalisation) will not be reported to the Sponsor of Research Ethics Committee as these are regarded as being part of the patient's usual clinical care.

03

Conditions studied

  • Heart Failure
  • Pacemaker

Browse trials for

Keywords

  • Heart failure
  • Artificial intelligence
  • Pacemaker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with previously implanted pacemakers for bradycardia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged ≥18 years
  • Patients with existing pacemakers who have a right ventricular pacing burden ≥20%.
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Patients who are unwilling or unable to provide .
  • Patients known to have heart failure
  • Patients with any previous measurement of \<50%.
  • Patients with conduction system pacemakers.
  • Patients with cardiac resynchronisation therapy pacemakers/defibrillators.
  • Patients with implantable cardioverter defibrillators.
  • Patients with leadless pacemakers.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
150 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The accuracy of artificial intelligence derived left ventricular ejection fraction (LVEF) compared to expert sonographer measured LVEF

    Determined by the individual equivalence coefficient of artificial intelligence (AI) derived left ventricular ejection fraction (LVEF) versus to sonographer measured LVEF. The accuracy of AI LVEF will be compared to sonographer measured LVEF for non-inferiority. The pre-determined non-inferiority margin is 0.25 for the upper bound of the 95% confidence interval for this comparison.

    Time frame: Day 1

Secondary outcomes

  1. Accuracy of artificial intelligence derived left ventricular ejection fraction of <50%

    The accuracy of artificial intelligence derived left ventricular ejection fraction (LVEF) of \<50% compared to standard cart-based echocardiography measurement of LVEF \<50% by biplane method, determined by sensitivity, specificity, positive and negative predictive values.

    Time frame: Day 1

  2. Prediction of left ventricular ejection fraction <50%

    The incremental improvement of a model to predict left ventricular ejection fraction (LVEF) \<50% in a population with pacemakers of the addition of artificial intelligence derived LVEF, point of care N-terminal B-type natriuretic peptide, or both.

    Time frame: Day 1

  3. The utility of artificial intelligence echocardiography

    The proportion of participants in whom it was not possible to determine artificial intelligence derived left ventricular ejection fraction (LVEF), LVEF measured by a sonographer using the biplane method, and subjective measurement of LVEF.

    Time frame: Day 1

07

Study locations

1 site
  • Cardiovascular Research Facility, Leeds General Infirmary
    Leeds, LS1 3EX, United Kingdom
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Sep 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2025
First posted
Jan 28, 2026
StartActual
Oct 7, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07372651
Collaborators
Leeds Hospitals Charity
Responsible party
Dr Sam Straw (Clinical Lecturer in Cardiology, University of Leeds) — Principal investigator
First posted
Jan 28, 2026
Start date
Oct 7, 2025
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Jan 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion